Canmax Technologies Co Ltd

Canmax Technologies maintains a conservative capital structure with a debt-to-equity ratio of 0.15, indicating a low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 3.64, suggesting strong short-term liquidity. However, the risk assessment flags a medium liquidity risk due to negative net cash after subtracting total debt.

Profitability metrics show a return on equity (ROE) of 2.79% and a return on assets (ROA) of 1.84%, both below the typical thresholds for high-performing chemical firms. These figures suggest that the company is generating modest returns relative to its equity and asset base. Gross profit of 421.73 million CNY and operating income of 435.88 million CNY indicate a relatively narrow margin structure, which is common in the commodity chemicals industry.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes in China. The absence of segment-specific revenue breakdowns limits the ability to assess the performance of individual product lines or geographic regions.

Looking ahead, the company is projected to maintain a stable revenue trajectory, with no significant growth or contraction expected in the next fiscal year. Capital expenditures of -446.55 million CNY suggest a reduction in investment in new projects or facilities, which may indicate a focus on cost optimization rather than expansion. This aligns with the company's current financial strategy of maintaining a strong liquidity position while managing debt levels.

The risk assessment highlights a low dilution risk, with no near-term pressure from share issuance or dilutive events. The company's diluted shares outstanding are equal to its basic shares, indicating no material dilution from stock options or convertible securities. However, the risk assessment notes a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt.

Recent filings and transcripts do not indicate any material events or strategic shifts. The company's financial performance remains consistent with its historical trends, and there are no disclosed regulatory or operational risks that would significantly impact its operations.

Operating and net margins significantly exceed commodity chemical medians, indicating best-in-class profitability efficiency.

Debt-to-equity ratio of 0.15 is well below the cohort median of 0.31, suggesting a conservative capital structure.

Cash conversion ratio of 2.12 outperforms the cohort median of 1.1, reflecting strong operational cash generation.

Net income surged 107.3% year-over-year in the latest period, demonstrating significant recent earnings growth.

Operating income increased by 125.0% year-over-year, highlighting a substantial improvement in core operational profitability.

Free cash flow deteriorated to negative 2.9 billion CNY in 2026, signaling severe liquidity pressure.

Long-term debt nearly doubled to 6.2 billion CNY in 2026, increasing financial leverage and credit risk.

The company faces high credit risk and medium liquidity risk according to internal risk flag assessments.

Revenue ¥7.55B, +14,2% YoY; Operating income −55,5% YoY.

• ▍Revenue ¥7.55B, +14,2% YoY
• ▍Operating income −55,5% YoY
• ▍Net income −51,8% YoY
• ▍Free cash flow −8 400,3% YoY
• ▍Net margin 5.3%

Revenue ¥10.47B, −38,5% YoY; Operating income −76,1% YoY.

• ▍Revenue ¥10.47B, −38,5% YoY
• ▍Operating income −76,1% YoY
• ▍Net income −74,8% YoY
• ▍Free cash flow −120,0% YoY
• ▍Net margin 15.8%

Revenue ¥17.03B, +401,3% YoY; Operating income +603,0% YoY.

• ▍Revenue ¥17.03B, +401,3% YoY
• ▍Operating income +603,0% YoY
• ▍Net income +623,2% YoY
• ▍Free cash flow +1 451,8% YoY
• ▍Net margin 38.7%

Revenue ¥3.40B; Operating income ¥1.47B.

• ▍Revenue ¥3.40B
• ▍Operating income ¥1.47B
• ▍Net margin 26.8%